Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Daré Bioscience, Inc. (NASDAQ: DARE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports when available, and exhibits such as press releases and corporate presentations that the company uses to communicate material information about its operations and strategy.
Daré’s recent 8-K filings illustrate several key themes. Some reports furnish earnings press releases and corporate updates, outlining financial results, cash position, research and development spending and the status of programs such as DARE to PLAY Sildenafil Cream, Ovaprene and other pipeline assets. Other 8-Ks describe interim clinical data for Ovaprene’s pivotal Phase 3 study, including data safety monitoring board recommendations and information on pregnancy rates, tolerability and study design.
Additional 8-K filings address corporate and listing matters, such as Nasdaq correspondence regarding compliance with Listing Rule 5550(b) for stockholders’ equity and market value of listed securities, and the company’s multi-step plan to maintain its listing on The Nasdaq Capital Market. There are also filings related to stock incentive plan amendments and stockholder meeting results, which provide detail on governance decisions and equity compensation arrangements.
Through Stock Titan, users can review Daré’s SEC filings in one place and use AI-powered tools to summarize complex documents. These tools can help explain the implications of items such as clinical trial updates, grant agreements, listing notices and capital-raising activities. Investors interested in Daré’s women’s health portfolio, regulatory status and financing strategy can use this page to monitor new 8-Ks and other filings as they are posted to EDGAR, and to quickly interpret how those disclosures relate to the company’s pipeline and commercialization plans.
Dare Bioscience (NASDAQ:DARE) disclosed that Nasdaq's Hearings Panel has amended its decision regarding the company's delisting appeal and approved their modified compliance plan. The company must demonstrate compliance with either the $2.5 million stockholders' equity requirement or maintain a $35 million minimum market value by July 31, 2025, with a final deadline of August 12, 2025. Dare has been non-compliant with these requirements since August 2024. The Panel reserves the right to delist the stock before the deadline if the company fails to execute its plan satisfactorily.